

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 8-K

BIOMARIN PHARMACEUTICAL INC

Form 8-K

November 02, 2001

=====

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):  
November 2, 2001 (November 2, 2001)

BioMarin Pharmaceutical Inc.  
(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation)	000-26727 (Commission File Number)	68-0397820 (IRS Employer Identification No.)
---	--	--

371 Bel Marin Keys Boulevard, Suite 210 Novato, California (Address of principal executive offices)	94949 (Zip Code)
--	---------------------

(415) 884-6700

-----  
(Registrant's telephone number, including area code)

=====

Edgar Filing: BIOMARIN PHARMACEUTICAL INC - Form 8-K

Item 5. Other Events

On November 2, 2001, we announced the results of our Phase III trial of Aldurazyme for the treatment of MPS I in a press release dated November 2, 2001. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

Item 7. Financial Statements and Exhibits

EXHIBIT NO.	DESCRIPTION OF DOCUMENT
99.1	Press Release Dated November 2, 2001 Related to the Announcement of the Results of the Phase III Trial of Aldurazyme for the Treatment of MPS I.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BioMarin Pharmaceutical Inc.

By: /s/ Raymond W. Anderson

Raymond W. Anderson  
Chief Operating Officer, Chief Financial  
Officer, Secretary and Vice President Finance  
and Administration

Date: November 2, 2001

Exhibit Index

EXHIBIT NO.	DESCRIPTION OF DOCUMENT
99.1	Press Release Dated November 2, 2001 Related to the Announcement of the Results of the Phase III Trial of Aldurazyme for the Treatment of MPS I.